Click here for slides on this topic


Combination therapy

The combination of different antihyperglycemic medications glucose levels among patients with type 2 diabetes.
The following content matched the glossary term: Combination therapy

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

Managing the Patient With Type 2 Diabetes and Heart Failure

Top

.style1 FONT FAMILY Arial, Helvetica, sans serif COLOR #004685

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

Association between intensification of metformin treatment with insulin vs sulfonylureas and CV events and all-cause mortality among patients with diabetes

Top

Roumie CL, Greevy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014;311(22):2288-2296.

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin + MDI insulin

Top

Rosenstock J, Jelaska A, Frappin G, et al; on behalf of the EMPA-REG MDI Trial Investigators. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014. DOI:10.2337/dc13-3055.

NDEI.org Expert Commentary on Type 2 Diabetes Prevention in SEQUEL from Vivian Fonseca

Top

NDEI Education Council Member Vivian A. Fonseca, MD, comments on type 2 diabetes prevention in a substudy of SEQUEL: “Weight loss alone may be an option to prevent type 2 diabetes”

NDEI.org Expert Commentary on Type 2 Diabetes Treatment Trends from Vivian Fonseca, MD

Top

NDEI Education Council Member Vivian A. Fonseca, MD, comments on a study exploring type 2 diabetes treatment trends in the U.S.: “Clinicians could use these data to determine whether their own prescribing has changed in line with national trends”

Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release

Top

Exclusive! Expert commentary from Vivian A. Fonseca, MD, on SEQUEL. Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014;37:912-921.

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012

Top

Exclusive! Expert commentary from Vivian A. Fonseca, MD, on this study. Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care. 2014;37:985-992.

1 2 3 4 5 6 7 8 9 Next 

Slide Library Results

Search Results for: Combination therapy Slides Found: 46
Sulfonylurea/Insulin Combination Therapy: Change in FPG and Insulin Dose
Effect of Sibutramine Plus Orlistat
Sulfonylurea/Insulin Combination Therapy: Change in FPG and Insulin Dose
Effect of Sitagliptin + Metformin on A1C in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on FPG in Patients with Type 2 Diabetes
Effect of Sitagliptin + Metformin on B-Cell Function at 24 Weeks
Effect of Sitagliptin Added to Glimepiride and/or Metformin in Patients With Type 2 Diabetes
Glycemic Control With Addition of Sitagliptin to Glimepiride and/or Metformin
Alogliptin and Glyburide Combination Therapy: A1C
RECORD: Study Design
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
CANOE: Low-Dose Combination Therapy With Rosiglitazone Plus Metformin for Diabetes Prevention
CANOE: Development of New-Onset Diabetes With Low-Dose Combination Therapy Vs Placebo
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Design
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Results
Effect of Liraglutide and Insulin on Cardiovascular Disease Risk Factors
Liraglutide Effect on Cardiovascular Disease: Results Among Patients Switched from Exenatide
ACP: Considerations for Oral Pharmacologic Therapy in Type 2 Diabetes
TINSAL-T2D Trial: Eligibility Criteria and Study Protocol
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Change in A1C from Baseline
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Adverse Events and All-Cause Mortality
ESH/ESC Hypertension Guidelines: Hypertension Treatment Options
nbESH/ESC Hypertension Guidelines: Hypertension Treatment for Patients With Nephropathy
ONTARGET: Similar CV Outcomes with Ramipril, Telmisartan, and Their Combination
ONTARGET: Significantly Increased Risk of Renal Impairment with Combination Therapy
ONTARGET: Significantly Increased Potassium Level with Combination Therapy
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, Change in A1C at 26 Weeks
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on A1C Levels in Patients With Type 2 Diabetes
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on A1C Levels in
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on Body Weight in
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
US Trends in Type 2 Diabetes Treatment, 1997-2012: Number of Treatments
Sulfonylurea Treatment All-Cause CV Mortality Type 2 Diabetes Treatment | NDEI
Higher CV Risk With Metformin + Sulfonylurea Vs DPP-4 Inhibitor | NDEI
DURATION-3 & LEAD-5 Post-Hoc Analysis Insulin Type 2 Diabetes PPT | NDEI
A1C Reduction GLP-1 RAs & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Similar A1C Goal Achievement GLP-1 RA & Glargine DURATION-3 & LEAD-5 | NDEI
Weight Loss With GLP-1 RA & Increase With Glargine in DURATION-3 & LEAD-5 | NDEI
Hypoglycemia With GLP-1 RA & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Empagliflozin Vs Linagliptin First-Line Type 2 Diabetes Treatment ENDO2015 | NDEI
Empagliflozin Vs Linagliptin 2nd-Line Therapy Type 2 Diabetes Obesity ENDO2015 | NDEI
AACE 2015 Diabetes Guidelines Dyslipidemia Treatment PPT | NDEI
AACE 2015 Guidelines Hypertension Management PPT | NDEI
Combination Statin Therapy in Type 2 Diabetes ADA Guidelines | NDEI PPT
Combination Lipid-Lowering Therapy NLA Cholesterol Guidelines PPT | CCMD